- Home
- JTAI vs ACXP Comparison
JTAI vs ACXP Comparison
Compare JTAI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- ACXP
- Stock Information
- Founded
- JTAI 2018
- ACXP 2017
- Country
- JTAI United States
- ACXP United States
- Employees
- JTAI N/A
- ACXP N/A
- Industry
- JTAI Blank Checks
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- JTAI Finance
- ACXP Health Care
- Exchange
- JTAI Nasdaq
- ACXP Nasdaq
- Market Cap
- JTAI 8.3M
- ACXP 9.1M
- IPO Year
- JTAI N/A
- ACXP 2021
- Fundamental
- Price
- JTAI $3.42
- ACXP $4.70
- Analyst Decision
- JTAI Strong Buy
- ACXP Strong Buy
- Analyst Count
- JTAI 1
- ACXP 3
- Target Price
- JTAI $11.00
- ACXP $143.67
- AVG Volume (30 Days)
- JTAI 67.8K
- ACXP 66.2K
- Earning Date
- JTAI 08-15-2025
- ACXP 08-12-2025
- Dividend Yield
- JTAI N/A
- ACXP N/A
- EPS Growth
- JTAI N/A
- ACXP N/A
- EPS
- JTAI N/A
- ACXP N/A
- Revenue
- JTAI $12,790,684.00
- ACXP N/A
- Revenue This Year
- JTAI $13.37
- ACXP N/A
- Revenue Next Year
- JTAI $201.13
- ACXP N/A
- P/E Ratio
- JTAI N/A
- ACXP N/A
- Revenue Growth
- JTAI N/A
- ACXP N/A
- 52 Week Low
- JTAI $2.30
- ACXP $3.80
- 52 Week High
- JTAI $57.17
- ACXP $47.80
- Technical
- Relative Strength Index (RSI)
- JTAI 52.51
- ACXP 33.75
- Support Level
- JTAI $3.01
- ACXP $4.40
- Resistance Level
- JTAI $3.54
- ACXP $5.29
- Average True Range (ATR)
- JTAI 0.17
- ACXP 0.51
- MACD
- JTAI 0.02
- ACXP 0.08
- Stochastic Oscillator
- JTAI 77.36
- ACXP 40.91
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.